Insider Transactions in Q3 2024 at Mbx Biosciences, Inc. (MBX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Ali Behbahani |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Ali Behbahani |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Forest Baskett |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Forest Baskett |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Edward T Mathers |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Edward T Mathers |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Mohamad Makhzoumi |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Mohamad Makhzoumi |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Anthony A. Florence Jr. |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Anthony A. Florence Jr. |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Carmen Chang |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Carmen Chang |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Scott D Sandell |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Scott D Sandell |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Rick Yang |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Rick Yang |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Paul Edward Walker |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Paul Edward Walker |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
James M Cornelius |
BUY
Conversion of derivative security
|
Direct |
102,082
+50.0%
|
-
|
|
Sep 16
2024
|
Frazier Life Sciences X, L.P. |
BUY
Open market or private purchase
|
Direct |
625,000
+12.07%
|
$10,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Frazier Life Sciences X, L.P. |
BUY
Conversion of derivative security
|
Direct |
3,927,774
+50.0%
|
-
|
|
Sep 16
2024
|
New Enterprise Associates 17, L.P. |
BUY
Open market or private purchase
|
Direct |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
New Enterprise Associates 17, L.P. |
BUY
Conversion of derivative security
|
Direct |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
750,000
+20.66%
|
$12,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,062,215
+50.0%
|
-
|
|
Sep 16
2024
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
750,000
+20.66%
|
$12,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
3,062,215
+50.0%
|
-
|
|
Sep 16
2024
|
Tiba Aynechi |
BUY
Open market or private purchase
|
Indirect |
750,000
+25.98%
|
$12,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Tiba Aynechi |
BUY
Conversion of derivative security
|
Indirect |
1,386,335
+50.0%
|
-
|
|
Sep 16
2024
|
P. Kent Hawryluk President & CEO |
BUY
Conversion of derivative security
|
Indirect |
115,914
+22.54%
|
-
|
|
Sep 16
2024
|
P. Kent Hawryluk President & CEO |
BUY
Conversion of derivative security
|
Direct |
283,846
+37.09%
|
-
|
|
Sep 16
2024
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
625,000
+12.07%
|
$10,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Patrick J Heron |
BUY
Conversion of derivative security
|
Indirect |
3,927,774
+50.0%
|
-
|
|
Sep 16
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
1,790,122
+34.2%
|
-
|